CHICAGO, Ill. (March 29, 2011)The growth and spread of breast cancer tumors may be delayed with a promising treatment that combines two innovative strategies: blocking the enzyme needed to "energize" cancer cells and infusing a potent drug directly into the tumor, with minimum exposure to healthy tissues, indicate researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
"Once breast cancer metastases have been detected, current treatments (such as surgical resection or tumor removal) may be ineffective. We've found a way to keep a breast cancer tumor dormantthus potentially increasing the likelihood that a tumor can be treated successfully," noted Jeff H. Geschwind, M.D., FSIR, professor of radiology, surgery and oncology and director of vascular and interventional radiology at Johns Hopkins University School of Medicine in Baltimore, Md. "Our study shows that an ultrasound-guided intra-tumoral treatment with a drug called 3-bromopyruvate (3-BrPA) may be a very promising new therapy for patients with breast cancer that delays tumor growth and spread," added Geschwind, who is also the director of the Interventional Radiology Center at Johns Hopkins University School of Medicine.
"Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women in the United States," said Geschwind. It was estimated that 207,090 women would be diagnosed withand 39,840 women would die ofcancer of the breast in 2010thus affecting one in eight women during their lives. "The development of new treatment options for this lethal disease is imperative," said Geschwind, indicating that once metastasis is detected, a patient may have (on average) only 18 to 24 months to live.
Increased awareness and screening has increased the likelihood of diagnosing early-stage cancer tumors, and breast cancer is treated in several ways, depending on the kind of breast cancer and how
|Contact: Maryann Verrillo|
Society of Interventional Radiology